Insight Molecular Diagnostics Inc. SEC filings IMDX
Insight Molecular Diagnostics Inc. has 688 filings in SEC EDGAR's recent list, going back to May 14, 2015. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 10, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 21, 2026 (material agreement). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Sep 21, 2026 | Sep 15, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Aug 10, 2026 | Aug 10, 2026 |
| S-8 | Employee stock plan registration | Jul 24, 2026 | — |
| 4 | Insider transaction | Jul 6, 2026 | Jul 1, 2026 |
| 4 | Insider transaction | Jul 6, 2026 | Jul 1, 2026 |
| 4 | Insider transaction | Jul 6, 2026 | Jul 1, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 17, 2026 | Jun 11, 2026 |
| 4 | Insider transaction | Jun 15, 2026 | Jun 11, 2026 |
| 4 | Insider transaction | Jun 15, 2026 | Jun 11, 2026 |
| 4 | Insider transaction | Jun 15, 2026 | Jun 11, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 13, 2026 | May 13, 2026 |
| 8-K/A |
Amended current report
Other events
|
May 13, 2026 | Feb 20, 2026 |
| ARS | Annual report to shareholders | Apr 30, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 30, 2026 | — |
| DEF 14A | Proxy statement | Apr 30, 2026 | Apr 30, 2026 |
| 8-K |
Current report
Other events
|
Apr 30, 2026 | Apr 30, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Apr 27, 2026 | — |
| 4 | Insider transaction | Apr 27, 2026 | Apr 23, 2026 |
| 4 | Insider transaction | Apr 20, 2026 | Apr 16, 2026 |
| 4 | Insider transaction | Mar 30, 2026 | Mar 26, 2026 |
| 4 | Insider transaction | Mar 30, 2026 | Mar 26, 2026 |
| 4 | Insider transaction | Mar 30, 2026 | Mar 26, 2026 |
| 10-K | Annual report | Mar 26, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 26, 2026 | Mar 26, 2026 |
| 8-K |
Current report
Material agreement
|
Feb 26, 2026 | Feb 20, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Feb 12, 2026 | — |
| 4 | Insider transaction | Feb 12, 2026 | Feb 10, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Feb 12, 2026 | Feb 10, 2026 |
| 424B5 | Prospectus supplement | Feb 11, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 11, 2026 | Feb 11, 2026 |
| 4/A | Filing | Nov 13, 2025 | Oct 31, 2025 |
| 10-Q | Quarterly report | Nov 10, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2025 | Nov 10, 2025 |
| 4 | Insider transaction | Nov 4, 2025 | Oct 31, 2025 |
| 8-K |
Current report
Officer or director change
|
Oct 2, 2025 | Sep 28, 2025 |
| 4 | Insider transaction | Sep 30, 2025 | Sep 28, 2025 |
| 4 | Insider transaction | Sep 30, 2025 | Sep 28, 2025 |
| 4 | Insider transaction | Sep 30, 2025 | Sep 28, 2025 |
| 8-K |
Current report
Officer or director change
|
Sep 19, 2025 | Sep 16, 2025 |
| S-8 | Employee stock plan registration | Aug 18, 2025 | — |
| 10-Q | Quarterly report | Aug 11, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2025 | Aug 11, 2025 |
| 4 | Insider transaction | Jul 3, 2025 | Jul 1, 2025 |
| 4 | Insider transaction | Jul 3, 2025 | Jul 1, 2025 |
| 4 | Insider transaction | Jul 3, 2025 | Jul 1, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jul 2, 2025 | Jun 27, 2025 |
| 8-K |
Current report
Bylaw or fiscal year change, Regulation FD disclosure
|
Jun 17, 2025 | Jun 13, 2025 |
| ARS | Annual report to shareholders | May 14, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | May 14, 2025 | — |
| DEF 14A | Proxy statement | May 14, 2025 | May 14, 2025 |
| 10-Q | Quarterly report | May 12, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 12, 2025 | May 12, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 9, 2025 | — |
| 8-K |
Current report
Auditor change
|
Apr 17, 2025 | Apr 11, 2025 |
| 424B3 | Prospectus | Apr 8, 2025 | — |
| EFFECT | Filing | Apr 7, 2025 | — |
| CORRESP | Letter to the SEC | Apr 4, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 3, 2025 | — |
| S-1 | Registration statement | Mar 28, 2025 | — |
| 4 | Insider transaction | Mar 28, 2025 | Mar 26, 2025 |
| 4 | Insider transaction | Mar 28, 2025 | Mar 26, 2025 |
| 4 | Insider transaction | Mar 28, 2025 | Mar 26, 2025 |
| 10-K | Annual report | Mar 24, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 24, 2025 | Mar 24, 2025 |
| 8-K |
Current report
Officer or director change
|
Mar 10, 2025 | Mar 4, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Mar 4, 2025 | — |
| D | Filing | Feb 24, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 14, 2025 | — |
| 4 | Insider transaction | Feb 11, 2025 | Feb 7, 2025 |
| 4 | Insider transaction | Feb 11, 2025 | Feb 7, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Feb 10, 2025 | — |
| 4 | Insider transaction | Feb 10, 2025 | Feb 6, 2025 |
| 8-K |
Current report
Material agreement, Agreement ended, Unregistered share sale, Regulation FD disclosure
|
Feb 10, 2025 | Feb 6, 2025 |
| 424B5 | Prospectus supplement | Feb 10, 2025 | — |
| 4 | Insider transaction | Feb 4, 2025 | Jan 31, 2025 |
| 4 | Insider transaction | Jan 31, 2025 | Jan 29, 2025 |
| 4 | Insider transaction | Jan 15, 2025 | Jan 13, 2025 |
| 8-K |
Current report
Material agreement
|
Jan 8, 2025 | Jan 2, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Dec 27, 2024 | — |
| 4 | Insider transaction | Dec 27, 2024 | Dec 26, 2024 |
| 3 | Initial insider ownership | Dec 27, 2024 | Dec 26, 2024 |
| 4 | Insider transaction | Dec 26, 2024 | Dec 26, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Dec 9, 2024 | — |
| 4 | Insider transaction | Dec 9, 2024 | Dec 5, 2024 |
| SC 13G | Ownership over 5% (passive) | Nov 14, 2024 | — |
| 10-Q | Quarterly report | Nov 12, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2024 | Nov 12, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Oct 24, 2024 | — |
| 424B3 | Prospectus | Oct 22, 2024 | — |
| EFFECT | Filing | Oct 21, 2024 | — |
| CORRESP | Letter to the SEC | Oct 21, 2024 | — |
| S-3/A | Filing | Oct 18, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 17, 2024 | — |
| S-3 | Shelf registration | Oct 16, 2024 | — |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Oct 15, 2024 | Oct 11, 2024 |
| 4 | Insider transaction | Oct 15, 2024 | Oct 11, 2024 |
| SC 13G | Ownership over 5% (passive) | Oct 9, 2024 | — |
| D | Filing | Oct 8, 2024 | — |
| 4 | Insider transaction | Oct 4, 2024 | Oct 2, 2024 |
| 4 | Insider transaction | Oct 4, 2024 | Oct 2, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure, Other events
|
Oct 3, 2024 | Oct 2, 2024 |
| DEF 14A | Proxy statement | Sep 25, 2024 | Sep 25, 2024 |
| 8-K |
Current report
Material agreement, Agreement ended
|
Aug 9, 2024 | Aug 9, 2024 |
| 424B5 | Prospectus supplement | Aug 9, 2024 | — |
| 10-Q | Quarterly report | Aug 8, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2024 | Aug 8, 2024 |
| EFFECT | Filing | Aug 7, 2024 | — |
| CORRESP | Letter to the SEC | Aug 7, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 6, 2024 | — |
| S-3 | Shelf registration | Aug 1, 2024 | — |
| 8-K |
Current report
Listing notice
|
Jul 12, 2024 | Jul 8, 2024 |
| 8-K |
Current report
Shareholder vote results, Other events
|
Jul 5, 2024 | Jun 28, 2024 |
| 4 | Insider transaction | Jul 3, 2024 | Jul 1, 2024 |
| 4 | Insider transaction | Jul 3, 2024 | Jul 1, 2024 |
| 4 | Insider transaction | Jul 3, 2024 | Jul 1, 2024 |
| 4 | Insider transaction | Jun 24, 2024 | Jun 20, 2024 |
| 3 | Initial insider ownership | Jun 24, 2024 | Jun 17, 2024 |
| 8-K |
Current report
Officer or director change
|
Jun 17, 2024 | Jun 17, 2024 |
| 424B3 | Prospectus | Jun 4, 2024 | — |
| 8-K |
Current report
Officer or director change
|
May 31, 2024 | May 30, 2024 |
| 8-K |
Current report
Officer or director change
|
May 23, 2024 | May 20, 2024 |
| 424B3 | Prospectus | May 23, 2024 | — |
| EFFECT | Filing | May 22, 2024 | — |
| 4 | Insider transaction | May 22, 2024 | May 20, 2024 |
| 4 | Insider transaction | May 22, 2024 | May 20, 2024 |
| 4 | Insider transaction | May 22, 2024 | May 20, 2024 |
| CORRESP | Letter to the SEC | May 21, 2024 | — |
| S-3/A | Filing | May 17, 2024 | — |
| 8-K |
Current report
Results of operations
|
May 15, 2024 | May 15, 2024 |
| 10-Q | Quarterly report | May 15, 2024 | Mar 31, 2024 |
| UPLOAD | Letter from the SEC | May 14, 2024 | — |
| S-3 | Shelf registration | May 10, 2024 | — |
| DEF 14A | Proxy statement | Apr 29, 2024 | Apr 29, 2024 |
| D | Filing | Apr 25, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Apr 22, 2024 | — |
| 10-K | Annual report | Apr 16, 2024 | Dec 31, 2023 |
| SC 13D/A | Amended ownership over 5% (active) | Apr 15, 2024 | — |
| 4 | Insider transaction | Apr 15, 2024 | Apr 11, 2024 |
| 4 | Insider transaction | Apr 15, 2024 | Apr 11, 2024 |
| 4 | Insider transaction | Apr 15, 2024 | Apr 11, 2024 |
| 8-K |
Current report
Material agreement, Results of operations, Unregistered share sale, Regulation FD disclosure, Other events
|
Apr 12, 2024 | Apr 11, 2024 |
| 8-K |
Current report
Material agreement, Other events
|
Apr 11, 2024 | Apr 5, 2024 |
| NT 10-K | Filing | Apr 1, 2024 | Dec 31, 2023 |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2024 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 23, 2024 | Jan 22, 2024 |
| 10-Q | Quarterly report | Nov 9, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2023 | Nov 9, 2023 |
| 4 | Insider transaction | Oct 12, 2023 | Oct 10, 2023 |
| 8-K/A |
Amended current report
Auditor change
|
Oct 10, 2023 | Oct 10, 2023 |
| 8-K |
Current report
Auditor change
|
Oct 5, 2023 | Sep 29, 2023 |
| 8-K |
Current report
Material agreement
|
Sep 20, 2023 | Sep 14, 2023 |
| 8-K |
Current report
Other events
|
Aug 28, 2023 | Aug 28, 2023 |
| 4 | Insider transaction | Aug 17, 2023 | Aug 15, 2023 |
| 10-Q | Quarterly report | Aug 10, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Aug 10, 2023 | Aug 4, 2023 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Shareholder vote results, Regulation FD disclosure
|
Jul 24, 2023 | Jul 24, 2023 |
| DEFA14A | Additional proxy material | Jul 21, 2023 | — |
| 8-K |
Current report
Officer or director change
|
Jul 14, 2023 | Jul 13, 2023 |
| DEF 14A | Proxy statement | Jul 10, 2023 | Jul 10, 2023 |
| 4 | Insider transaction | Jul 3, 2023 | Jun 30, 2023 |
| PRE 14A | Preliminary proxy statement | Jun 30, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 29, 2023 | Jun 23, 2023 |
| 4 | Insider transaction | Jun 27, 2023 | Jun 23, 2023 |
| 4 | Insider transaction | Jun 27, 2023 | Jun 23, 2023 |
| 4 | Insider transaction | Jun 27, 2023 | Jun 23, 2023 |
| 4 | Insider transaction | Jun 27, 2023 | Jun 23, 2023 |
| 4 | Insider transaction | Jun 15, 2023 | Jun 14, 2023 |
| 4 | Insider transaction | Jun 13, 2023 | Jun 9, 2023 |
| 8-K |
Current report
Officer or director change
|
Jun 9, 2023 | Jun 6, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 6, 2023 | Jun 6, 2023 |
| DEFR14A | Filing | May 22, 2023 | — |
| DEF 14A | Proxy statement | May 19, 2023 | May 19, 2023 |
| 10-Q | Quarterly report | May 15, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Results of operations, Officer or director change
|
May 11, 2023 | May 11, 2023 |
| 10-K/A | Amended annual report | May 1, 2023 | Dec 31, 2022 |
| 4 | Insider transaction | Apr 18, 2023 | Apr 14, 2023 |
| 4/A | Form 4/a submission | Apr 18, 2023 | Mar 6, 2023 |
| SC 13G/A | Amended ownership over 5% (passive) | Apr 14, 2023 | — |
| 8-K |
Current report
Exit or restructuring costs
|
Apr 13, 2023 | Apr 12, 2023 |
| 10-K | Annual report | Apr 12, 2023 | Dec 31, 2022 |
| 4 | Insider transaction | Apr 7, 2023 | Apr 5, 2023 |
| SC 13D/A | Amended ownership over 5% (active) | Apr 7, 2023 | — |
| 8-K |
Current report
Material agreement
|
Apr 6, 2023 | Apr 3, 2023 |
| 424B5 | Prospectus supplement | Apr 6, 2023 | — |
| 4 | Insider transaction | Apr 5, 2023 | Apr 3, 2023 |
| 4 | Insider transaction | Apr 5, 2023 | Apr 3, 2023 |
| 4 | Insider transaction | Apr 5, 2023 | Apr 3, 2023 |
| 8-K |
Current report
Results of operations, Other events
|
Apr 5, 2023 | Apr 5, 2023 |
| NT 10-K | Filing | Apr 3, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 31, 2023 | Mar 31, 2023 |
| 4 | Insider transaction | Mar 8, 2023 | Mar 6, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Mar 2, 2023 | Feb 24, 2023 |
| 4 | Insider transaction | Feb 28, 2023 | Feb 24, 2023 |
| 4 | Insider transaction | Feb 28, 2023 | Feb 24, 2023 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Regulation FD disclosure
|
Feb 23, 2023 | Feb 16, 2023 |
| 8-K/A |
Amended current report
Shareholder vote results
|
Feb 17, 2023 | Jul 15, 2022 |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2023 | — |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- IMDX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- CA
- Headquarters
- Nashville, TN
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1642380
- Former names
- OncoCyte Corp (until Jun 17, 2025); Oncocyte Corp (until Jun 17, 2025)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.